Hicham Zegzouti, Ph. D.

Senior Research Scientist
Promega Corporation

Hicham Zegzouti is a Senior Research Scientist in the Assay Design Division of Research & Development at Promega Corporation. He is interested in the molecular and biochemical processes that regulate cellular signaling and cell-cell communications. His group develops Assay technologies to interrogate diverse enzyme activities and cellular pathways such as kinases, glycosyltransferases, epigenetic enzymes and other drug targets.
Hicham Zegzouti received his Ph.D. in 1997 from the National Polytechnic Institute of Toulouse (INPT), France, he has authored 26 journal articles and book chapters, co-edited one methods and protocols book and he is an inventor on three issued patents.

Poster(s):

• Screening inhibitors and monitoring the efficacy of neutralizing antibodies in convalescent and vaccinated patient samples with Lumit SARS-CoV-2 Spike RBD:ACE2 immunoassay

• Profiling oncogenic Ras mutant drugs with homogeneous bioluminescent Lumit immunoassays